Loading…
Reported covered position: Rep. Sheila Jackson Lee (TX-18), Scheduler; Rep. Maxine Waters (CA-43), Scheduler; Rep. Eddie Bernice Johnson (TX-30), Dir. of Operations & Health Legis. Asst. and later Dep. Chief of Staff; Rep. Yvette D. Clarke (NY-09), Dep. Chief of Staff.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
PSA Screening for HIM Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2022 · third_quarter · Q3
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Source: Senate LDA
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration; S. 2599/H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action."
United States Innovation and Competition Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities. Policies related to the reauthorization of the Prescription Drug User Fee Act. Policies related to the FDA in S. 1260, "US Innovation and Competition Act," and HR 4521, "America COMPETES Act." Issues related to platform technologies and other FDA-related provisions in S. 3799, "PREVENT Pandemics Act."
United States Innovation and Competition Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - "Build Back Better Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Food and Drug Amendments of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Food and Drug Amendments of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
United States Innovation and Competition Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities. Policies related to the reauthorization of the Prescription Drug User Fee Act. Policies related to the FDA in S. 1260, "US Innovation and Competition Act," and HR 4521, "America COMPETES Act." Issues related to platform technologies and other FDA-related provisions in S. 3799, "PREVENT Pandemics Act."
United States Innovation and Competition Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration; S. 2599/H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action."
PREVENT Pandemics Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
PREVENT Pandemics Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
PREVENT Pandemics Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities. Policies related to the reauthorization of the Prescription Drug User Fee Act. Policies related to the FDA in S. 1260, "US Innovation and Competition Act," and HR 4521, "America COMPETES Act." Issues related to platform technologies and other FDA-related provisions in S. 3799, "PREVENT Pandemics Act."
FDASLA Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
FDASLA Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
A resolution supporting the goals and ideals of World Sickle Cell Awareness Day.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"); S Res 477, expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; HR 6000, "Cures 2.0"; and, Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act," and Senate companion legislation (no specific bill).
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"); S Res 477, expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; HR 6000, "Cures 2.0"; and, Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act," and Senate companion legislation (no specific bill).
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"); S Res 477, expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; HR 6000, "Cures 2.0"; and, Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act," and Senate companion legislation (no specific bill).
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act," and related provisions debated in Senate (no specific bill).
Cures 2.0 Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"); S Res 477, expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; HR 6000, "Cures 2.0"; and, Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act," and Senate companion legislation (no specific bill).
Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"); S Res 477, expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; HR 6000, "Cures 2.0"; and, Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act," and Senate companion legislation (no specific bill).
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
A resolution expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"); S Res 477, expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; HR 6000, "Cures 2.0"; and, Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act," and Senate companion legislation (no specific bill).
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2022 · second_quarter · Q2
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - "Build Back Better Act."
Issues related to funding for the Food and Drug Administration; S. 2599/H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action."
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2022 · first_quarter · Q1
General education about FDA approval policies and NIH research activities. Policies related to the reauthorization of the Prescription Drug User Fee Act. Policies related to the FDA in S. 1260, "US Innovation and Competition Act," and HR 4521, "America COMPETES Act." Issues related to platform technologies and other FDA-related provisions in S. 3799, "PREVENT Pandemics Act."
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act."
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2021 · fourth_quarter · Q4
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act," and related provisions debated in Senate (no specific bill).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"); S Res 477, expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; HR 6000, "Cures 2.0"; and, Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act," and Senate companion legislation (no specific bill).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2021 · third_quarter · Q3
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act."
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2021 · second_quarter · Q2
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE